[1]
Geller, M.J. Ancient Babylonian medicine; Wiley-Blackwell: Malden, 2010.
[2]
Selwyn, S. The topical treatment of skin infection.in: Maibach,
H.I.; Aly, R. (Eds.) Skin MicrobiologyRelevance to Clinical Infection; Springer-Verlag: New York, 1981, pp. 317-328.
[3]
Ebbell, B. The Papyrus Ebers: the greatest Egyptian medical
document. Levin & Munksgaard, Copenhagen., 1937.
[4]
Moghimi, H.R.; Shafizade, A.; Kamlinejad, M. Drug delivery
systems in Iranian traditional pharmacy (in Persian).Traditional
Medicine and Materia Medica Research Center, SBMU, Tehran,
Iran,, 2011.
[5]
Morgan, W.F. Poisoning by the external application of belladonna. BMJ, 1866, 2, 621.
[6]
Laws, G.E. Nitroglycerin head. J. Amer. Med. Assoc., 1910, 54, 793.
[7]
Schwenkenbecker, A. Das Absorptionsvermögen der Haut. Archiv. für Physiol, 1904, 1(2), 121-165.
[8]
Rein, H. Experimental electroendosmotic studies on living human skin. Z. Biol., 1924, 81, 124.
[9]
Moore, C.R.; Lamar, J.K.; Beck, N. Cutaneous absorption of sex hormones. J. Am. Med. Assoc., 1938, 111, 11-14.
[10]
Zondek, B. Cutaneous application of follicular hormone. Lancet, 1938, 1, 1474.
[11]
Zondek, B. The excretion of halogenated phenols and their use in the treatment of urogenital infections. J. Urol., 1942, 48, 747-758.
[12]
Fox, M.J.; Leslie, C.L. Treatment of Raynaud’s diseases with nitroglycerine. Wis. Med. J., 1948, 47, 855-858.
[13]
Lund, F. Percutaneous nitroglycerin treatment in cases of peripheral circulatory disorders, especially Raynaud’s disease. Acta Med. Scand., 1948, 131, 196-206.
[14]
Rothman, S. The principles of percutaneous absorption. J. Lab. Clin. Med., 1943, 28, 1305-1321.
[15]
Higuchi, T. Physical chemical analysis of percutaneous absorption processes. J. Soc. Cosmet. Chem., 1960, 11, 85-97.
[16]
Roberts, M.S.; Anderson, R.A.; Swarbrick, J. Permeability of human epidermis to phenolic compounds. J. Pharm. Pharmacol., 1977, 29, 677-683.
[17]
Katz, M.; Poulsen, B.J. Absorption of drugs through the skin.in:
Brodie, B.B.; Gilette, J. (Eds.)Handbook of Experimental Pharmacology; Springer Verlag, Berlin, 1971, pp. 103-174.
[18]
Scheuplein, R.J.; Blank, I.H. Permeability of the skin. Physiol. Rev., 1971, 51, 702-747.
[19]
Roberts, M.S.; Anderson, R.A.; Swarbrick, J.; Moore, D.E. The percutaneous absorption of phenolic compounds: the mechanism of diffusion across the stratum corneum. J. Pharm. Pharmacol., 1978, 30, 486-490.
[20]
Michaels, A.S.; Chandrasekaran, S.K.; Shaw, J.E. Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE J., 1975, 21, 985-996.
[21]
Pastore, M.N.; Kalia, Y.N.; Horstmann, M.; Roberts, M.S. Transdermal patches: History, development and pharmacology. Br. J. Pharmacol., 2015, 172, 2179-2209.
[22]
Isaac, M.; Holvey, C. Transdermal patches: The emerging mode of drug delivery system in psychiatry. Ther. Adv. Psychopharmacol., 2012, 2, 255-263.
[23]
McAfee, D.A.; Hadgraft, J.; Lane, M.E. Rotigotine: The first new chemical entity for transdermal drug delivery. Eur. J. Pharm. Biopharm., 2014, 88, 586-593.
[24]
Crank, J. The mathematics of diffusion, 2nd ed; Clarendon Press: Oxford, UK, 1979.
[25]
Yousef, S.; Liu, X.; Mostafa, A.; Mohammed, Y.; Grice, J.E.; Anissimov, Y.G.; Sakran, W.; Roberts, M.S. estimating maximal in vitro skin permeation flux from studies using non-sink receptor phase conditions. Pharm. Res., 2016, 33, 2180-2194.
[26]
Roberts, M.S.; Mohammed, Y.; Pastore, M.N.; Namjoshi, S.; Yousef, S.; Alinaghi, A.; Haridass, I.N.; Abd, E.; Leite-Silva, V.R.; Benson, H.; Grice, J.E. Topical and cutaneous delivery using nanosystems. J. Control. Release, 2017, 247, 86-105.
[27]
Nastiti, C.M.R.R.; Ponto, T.; Abd, E.; Grice, J.E.; Benson, H.A.E.; Roberts, M.S. Topical nano and microemulsions for skin delivery. Pharmaceutics, 2017, 9, E37.
[28]
Ita, K.B. Chemical penetration enhancers for transdermal drug delivery-success and challenges. Curr. Drug Deliv., 2015, 12, 645-651.
[29]
Alkilani, A.Z.; McCrudden, M.T.; Donnelly, R.F. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics, 2015, 7, 438-470.
[30]
McClements, D.J. Nanoemulsions versus microemulsions: Clarification of critical differences. Soft Matter, 2012, 8, 1719-1729.
[31]
Abd, E.; Namjoshi, S.; Mohammed, Y.H.; Roberts, M.S.; Grice, J.E. Synergistic skin penetration enhancer and nanoemulsion formulations promote the human epidermal permeation of caffeine and naproxen. J. Pharm. Sci., 2016, 105, 212-220.
[32]
Muller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54(Suppl. 1), S131-S155.
[33]
Jenning, V.; Gysler, A.; Schafer-Korting, M.; Gohla, S.H. Vitamin A loaded solid lipid nanoparticles for topical use: Occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm., 2000, 49, 211-218.
[34]
Zhang, Y.T.; Wu, Z.H.; Zhang, K.; Zhao, J.H.; Ye, B.N.; Feng, N.P. An in vitro and in vivo comparison of solid and liquid-oil cores in transdermal aconitine nanocarriers. J. Pharm. Sci., 2014, 103, 3602-3610.
[35]
Wissing, S.A.; Muller, R.H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity--in vivo study. Eur. J. Pharm. Biopharm., 2003, 56, 67-72.
[36]
Khurana, S.; Bedi, P.M.; Jain, N.K. Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam. Chem. Phys. Lipids, 2013, 175-176, 65-72.
[37]
Shrotriya, S.; Ranpise, N.; Satpute, P.; Vidhate, B. Skin targeting of curcumin solid lipid nanoparticles-engrossed topical gel for the treatment of pigmentation and irritant contact dermatitis. Artif. Cells Nanomed. Biotechnol., 2018, 46, 1471-1482.
[38]
Jin, S.E.; Kim, C.K. Charge-mediated topical delivery of plasmid DNA with cationic lipid nanoparticles to the skin. Colloids Surf. B Biointerfaces, 2014, 116, 582-590.
[39]
Xia, Q.; Saupe, A.; Muller, R.H.; Souto, E.B. Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int. J. Cosmetic. Sci., 2007, 29, 473-482.
[40]
Pople, P.V.; Singh, K.K. Development and evaluation of colloidal modified nanolipid carrier: Application to topical delivery of tacrolimus. Eur. J. Pharm. Biopharm., 2011, 79, 82-94.
[41]
Pople, P.V.; Singh, K.K. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus, Part II--in vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis. Eur. J. Pharm. Biopharm., 2013, 84, 72-83.
[42]
Patlolla, R.R.; Desai, P.R.; Belay, K.; Singh, M.S. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials, 2010, 31, 5598-5607.
[43]
Shah, P.P.; Desai, P.R.; Channer, D.; Singh, M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J. Control. Release, 2012, 161, 735-745.
[44]
Cevc, G. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 1996, 13, 257-388.
[45]
De Marco Almeida, F.; Silva, C.N.; de Araujo Lopes, S.C.; Santos, D.M.; Torres, F.S.; Cardoso, F.L.; Martinelli, P.M.; da Silva, E.R.; de Lima, M.E.; Miranda, L.A.F.; Oliveira, M.C. Physicochemical characterization and skin permeation of cationic transfersomes containing the synthetic peptide PnPP-19. Curr. Drug Deliv., 2018, 15, 1064-1071.
[46]
Manconi, M.; Manca, M.L.; Caddeo, C.; Valenti, D.; Cencetti, C.; Diez-Sales, O.; Nacher, A.; Mir-Palomo, S.; Terencio, M.C.; Demurtas, D.; Gomez-Fernandez, J.C.; Aranda, F.J.; Fadda, A.M.; Matricardi, P. Nanodesign of new self-assembling core-shell gellan-transfersomes loading baicalin and in vivo evaluation of repair response in skin. Nanomedicine, 2018, 14, 569-579.
[47]
Garg, V.; Singh, H.; Bimbrawh, S.; Singh, S.K.; Gulati, M.; Vaidya, Y.; Kaur, P. Ethosomes and transfersomes: Principles, perspectives and practices. Curr. Drug Deliv., 2017, 14, 613-633.
[48]
Godin, B.; Touitou, E. Ethosomes: New prospects in transdermal delivery. Crit. Rev. Ther. Drug Carrier Syst., 2003, 20, 63-102.
[49]
Das, S.K.; Chakraborty, S.; Roy, C.; Rajabalaya, R.; Mohaimin, A.W.; Khanam, J.; Nanda, A.; David, S.R. Ethosomes as novel vesicular carrier: An overview of the principle, preparation and its applications. Curr. Drug Deliv., 2018, 15, 795-817.
[50]
Muzzalupo, R.; Tavano, L.; Cassano, R.; Trombino, S.; Ferrarelli, T.; Picci, N. A new approach for the evaluation of niosomes as effective transdermal drug delivery systems. Eur. J. Pharm. Biopharm., 2011, 79, 28-35.
[51]
Manosroi, J.; Khositsuntiwong, N.; Manosroi, W.; Gotz, F.; Werner, R.G.; Manosroi, A. Potent enhancement of transdermal absorption and stability of human tyrosinase plasmid (pAH7/Tyr) by Tat peptide and an entrapment in elastic cationic niosomes. Drug Deliv., 2013, 20, 10-18.
[52]
Dragicevic-Curic, N.; Scheglmann, D.; Albrecht, V.; Fahr, A. Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies. J. Control. Release, 2008, 127, 59-69.
[53]
Shah, S.M.; Ashtikar, M.; Jain, A.S.; Makhija, D.T.; Nikam, Y.; Gude, R.P.; Steiniger, F.; Jagtap, A.A.; Nagarsenker, M.S.; Fahr, A. LeciPlex, invasomes, and liposomes: A skin penetration study. Int. J. Pharm., 2015, 490, 391-403.
[54]
Geusens, B.; Van Gele, M.; Braat, S.; De Smedt, S.C.; Stuart, M.C.; Prow, T.W.; Sanchez, W.; Roberts, M.S.; Sanders, N.; Lambert, J. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv. Functional. Mater., 2010, 20, 4077-4090.
[55]
Bracke, S.; Carretero, M.; Guerrero-Aspizua, S.; Desmet, E.; Illera, N.; Navarro, M.; Lambert, J.; Del Rio, M. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: Development of siRNA SECosome-based novel therapies. Exp. Dermatol., 2014, 23, 199-201.
[56]
Mura, S.; Manconi, M.; Fadda, A.M.; Sala, M.C.; Perricci, J.; Pini, E.; Sinico, C. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil: In vitro evaluation of drug permeation by infrared spectroscopy. Pharm. Dev. Technol., 2013, 18, 1339-1345.
[57]
Manconi, M.; Caddeo, C.; Sinico, C.; Valenti, D.; Mostallino, M.C.; Biggio, G.; Fadda, A.M. Ex vivo skin delivery of diclofenac by transcutol containing liposomes and suggested mechanism of vesicle-skin interaction. Eur. J. Pharm. Biopharm., 2011, 78, 27-35.
[58]
Manca, M.L.; Manconi, M.; Zaru, M.; Valenti, D.; Peris, J.E.; Matricardi, P.; Maccioni, A.M.; Fadda, A.M. Glycerosomes: Investigation of role of 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC) on the assembling and skin delivery performances. Int. J. Pharm., 2017, 532, 401-407.
[59]
Dreier, J.; Sorensen, J.A.; Brewer, J.R. Superresolution and fluorescence dynamics evidence reveal that intact liposomes do not cross the human skin barrier. PloS One, 2016, 11, e0146514.
[60]
Brewer, J.; Bloksgaard, M.; Kubiak, J.; Sorensen, J.A.; Bagatolli, L.A. Spatially resolved two-color diffusion measurements in human skin applied to transdermal liposome penetration. J. Invest. Dermatol., 2013, 133, 1260-1268.
[61]
Cevc, G.; Gebauer, D. Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. Biophysical. J., 2003, 84, 1010-1024.
[62]
Dragicevic-Curic, N.; Fahr, A. Liposomes in topical photodynamic therapy. Exp Opinion. Drug Deliv., 2012, 9, 1015-1032.
[63]
Dragicevic-Curic, N.; Grafe, S.; Gitter, B.; Winter, S.; Fahr, A. Surface charged temoporfin-loaded flexible vesicles: In vitro skin penetration studies and stability. Int. J. Pharm., 2010, 384, 100-108.
[64]
Yu, D.G.; Li, J.J.; Williams, G.R.; Zhao, M. Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review. J. Control. Release, 2018, 292, 91-110.
[65]
Li, J.J.; Yang, Y.Y.; Yu, D.G.; Du, Q.; Yang, X.L. Fast dissolving drug delivery membrane based on the ultra-thin shell of electrospun core-shell nanofibers. Eur. J. Pharm. Sci., 2018, 122, 195-204.
[66]
Hai, T.; Wan, X.; Yu, D-G.; Wang, K.; Yang, Y.; Liu, Z-P. Electrospun lipid-coated medicated nanocomposites for an improved drug sustained-release profile. Mater. Des., 2019, 162, 70-79.
[67]
Mitragotri, S. Devices for overcoming biological barriers: The use of physical forces to disrupt the barriers. Adv. Drug Deliv. Rev., 2013, 65, 100-103.
[68]
Denet, A.R.; Vanbever, R.; Preat, V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev., 2004, 56, 659-674.
[69]
Blagus, T.; Markelc, B.; Cemazar, M.; Kosjek, T.; Preat, V.; Miklavcic, D.; Sersa, G. In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery. J. Control. Release, 2013, 172, 862-871.
[70]
Prausnitz, M.R. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliv. Rev., 1999, 35, 61-76.
[71]
Bommannan, D.B.; Tamada, J.; Leung, L.; Potts, R.O. Effect of electroporation on transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH) in vitro. Pharm. Res., 1994, 11, 1809-1814.
[72]
Chang, S.L.; Hofmann, G.A.; Zhang, L.; Deftos, L.J.; Banga, A.K. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J. Control. Release, 2000, 66, 127-133.
[73]
Prausnitz, M.R.; Edelman, E.R.; Gimm, J.A.; Langer, R.; Weaver, J.C. Transdermal delivery of heparin by skin electroporation. Biotechnology, 1995, 13, 1205-1209.
[74]
Hooper, J.W.; Golden, J.W.; Ferro, A.M.; King, A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine, 2007, 25, 1814-1823.
[75]
Rosati, M.; Valentin, A.; Jalah, R.; Patel, V.; von Gegerfelt, A.; Bergamaschi, C.; Alicea, C.; Weiss, D.; Treece, J.; Pal, R.; Markham, P.D.; Marques, E.T.; August, J.T.; Khan, A.; Draghia-Akli, R.; Felber, B.K.; Pavlakis, G.N. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine, 2008, 26, 5223-5229.
[76]
Shen, X.; Soderholm, J.; Lin, F.; Kobinger, G.; Bello, A.; Gregg, D.A.; Broderick, K.E.; Sardesai, N.Y. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine, 2012, 30, 6946-6954.
[77]
Zorec, B.; Becker, S.; Rebersek, M.; Miklavcic, D.; Pavselj, N. Skin electroporation for transdermal drug delivery: The influence of the order of different square wave electric pulses. Int. J. Pharm., 2013, 457, 214-223.
[78]
Kalia, Y.N.; Naik, A.; Garrison, J.; Guy, R.H. Iontophoretic drug delivery. Adv. Drug Deliv. Rev., 2004, 56, 619-658.
[79]
Marro, D.; Kalia, Y.N.; Delgado-Charro, M.B.; Guy, R.H. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm. Res., 2001, 18, 1701-1708.
[80]
Marro, D.; Kalia, Y.N.; Delgado-Charro, M.B.; Guy, R.H. Optimizing iontophoretic drug delivery: Identification and distribution of the charge-carrying species. Pharm. Res., 2001, 18, 1709-1713.
[81]
Guy, R.H.; Kalia, Y.N.; Delgado-Charro, M.B.; Merino, V.; Lopez, A.; Marro, D. Iontophoresis: Electrorepulsion and electroosmosis. J. Control. Release, 2000, 64, 129-132.
[82]
Gratieri, T.; Kalia, Y.N. Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers. Int. J. Pharm., 2014, 460, 24-27.
[83]
Abla, N.; Naik, A.; Guy, R.H.; Kalia, Y.N. Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. J. Control. Release, 2005, 108, 319-330.
[84]
Azagury, A.; Khoury, L.; Enden, G.; Kost, J. Ultrasound mediated transdermal drug delivery. Adv. Drug Deliv. Rev., 2014, 72, 127-143.
[85]
Polat, B.E.; Hart, D.; Langer, R.; Blankschtein, D. Ultrasound-mediated transdermal drug delivery: Mechanisms, scope, and emerging trends. J. Control. Release, 2011, 152, 330-348.
[86]
Krasovitski, B.; Frenkel, V.; Shoham, S.; Kimmel, E. Intramembrane cavitation as a unifying mechanism for ultrasound-induced bioeffects. Proc. Natl. Acad. Sci. USA, 2011, 108, 3258-3263.
[87]
Benson, H.A.E.; McElnay, J.C.; Harland, R. Phonophoresis of lignocaine and prilocaine from Emla cream. Int. J. Pharm., 1988, 44, 65-69.
[88]
McElnay, J.C.; Benson, H.A.E.; Harland, R.; Hadgraft, J. Phonophoresis of methyl nicotinate: A preliminary study to elucidate the mechanism of action. Pharm. Res., 1993, 10, 1726-1731.
[89]
Benson, H.A.E.; McElnay, J.C. Transmission of ultrasound energy through topical pharmaceutical products. Physiotherapy, 1988, 74, 587-589.
[90]
Mitragotri, S.; Kost, J. Low-frequency sonophoresis: A review. Adv. Drug Deliv. Rev., 2004, 56, 589-601.
[91]
Schoellhammer, C.M.; Polat, B.E.; Mendenhall, J.; Maa, R.; Jones, B.; Hart, D.P.; Langer, R.; Blankschtein, D. Rapid skin permeabilization by the simultaneous application of dual-frequency, high-intensity ultrasound. J. Control. Release, 2012, 163, 154-160.
[92]
Park, E.J.; Werner, J.; Smith, N.B. Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm. Res., 2007, 24, 1396-1401.
[93]
Doukas, A.G.; Kollias, N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev., 2004, 56, 559-579.
[94]
Murthy, S.N.; Sammeta, S.M.; Bowers, C. Magnetophoresis for enhancing transdermal drug delivery: Mechanistic studies and patch design. J. Control. Release, 2010, 148, 197-203.
[95]
Krishnan, G.; Edwards, J.; Chen, Y.; Benson, H.A.E. Enhanced skin permeation of naltrexone by pulsed electromagnetic fields in human skin in vitro. J. Pharm. Sci., 2010, 99, 2724-2731.
[96]
Vicenzino, B.; Lawrenson, P.; Khan, A.; Stephenson, A.; Heales, L.; Benson, H.A.E. Wright. A. A randomised pilot equivalence trial to evaluate 1 diamagnetically enhanced transdermal delivery of key ground substance components in comparison to an established transdermal non-steroidal anti-inflammatory formulation in males with prior knee injury. PLoS One, 2019. [Epub ahead of print].
[97]
Mohammed, Y.H.; Yamada, M.; Lin, L.L.; Grice, J.E.; Roberts, M.S.; Raphael, A.P.; Benson, H.A.; Prow, T.W. Microneedle enhanced delivery of cosmeceutically relevant peptides in human skin. PloS One, 2014, 9, e101956.
[98]
Karimipour, D.J.; Karimipour, G.; Orringer, J.S. Microdermabrasion: An evidence-based review. Plast. Reconstr. Surg., 2010, 125, 372-377.
[99]
Andrews, S.N.; Zarnitsyn, V.; Bondy, B.; Prausnitz, M.R. Optimization of microdermabrasion for controlled removal of stratum corneum. Int. J. Pharm., 2011, 407, 95-104.
[100]
Andrews, S.; Lee, J.W.; Prausnitz, M. Recovery of skin barrier after stratum corneum removal by microdermabrasion. AAPS PharmSciTech, 2011, 12, 1393-1400.
[101]
Zhou, Y.; Banga, A.K. Enhanced delivery of cosmeceuticals by microdermabrasion. J. Cosmet. Dermatol., 2011, 10, 179-184.
[102]
Lee, W.R.; Tsai, R.Y.; Fang, C.L.; Liu, C.J.; Hu, C.H.; Fang, J.Y. Microdermabrasion as a novel tool to enhance drug delivery via the skin: An animal study. Dermatol. Surg., 2006, 32, 1013-1022.
[103]
Andrews, S.; Lee, J.W.; Choi, S.O.; Prausnitz, M.R. Transdermal insulin delivery using microdermabrasion. Pharm. Res., 2011, 28, 2110-2118.
[104]
Linkner, R.V.; Jim On, S.; Haddican, M.; Singer, G.; Shim-Chang, H. Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split-face, randomized, double-blind pilot study. J. Clin. Aesthetic. Dermatol., 2014, 7, 32-35.
[105]
Lee, J.W.; Gadiraju, P.; Park, J.H.; Allen, M.G.; Prausnitz, M.R. Microsecond thermal ablation of skin for transdermal drug delivery. J. Control. Release, 2011, 154, 58-68.
[106]
Bramson, J.; Dayball, K.; Evelegh, C.; Wan, Y.H.; Page, D.; Smith, A. Enabling topical immunization via microporation: A novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther., 2003, 10, 251-260.
[107]
Sintov, A.C.; Krymberk, I.; Daniel, D.; Hannan, T.; Sohn, Z.; Levin, G. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. J. Control. Release, 2003, 89, 311-320.
[108]
Levin, G.; Gershonowitz, A.; Sacks, H.; Stern, M.; Sherman, A.; Rudaev, S.; Zivin, I.; Phillip, M. Transdermal delivery of human growth hormone through RF-microchannels. Pharm. Res., 2005, 22, 550-555.
[109]
Lin, C.H.; Aljuffali, I.A.; Fang, J.Y. Lasers as an approach for promoting drug delivery via skin. Exp Opin. Drug Deliv., 2014, 11, 599-614.
[110]
Scheiblhofer, S.; Strobl, A.; Hoepflinger, V.; Thalhamer, T.; Steiner, M.; Thalhamer, J.; Weiss, R. Skin vaccination via fractional infrared laser ablation - Optimization of laser-parameters and adjuvantation. Vaccine, 2017, 35, 1802-1809.
[111]
Scheiblhofer, S.; Thalhamer, J.; Weiss, R. Laser microporation of the skin: Prospects for painless application of protective and therapeutic vaccines. Exp Opin. Drug Deliv., 2013, 10, 761-773.
[112]
Rkein, A.; Ozog, D.; Waibel, J.S. Treatment of atrophic scars with fractionated CO2 laser facilitating delivery of topically applied poly-L-lactic acid. Dermatol. Surg., 2014, 40, 624-631.
[113]
Lee, W.R.; Shen, S.C.; Aljuffali, I.A.; Li, Y.C.; Fang, J.Y. Impact of different vehicles for laser-assisted drug permeation via skin: Full-surface versus fractional ablation. Pharm. Res., 2014, 31, 382-393.
[114]
Lee, W.R.; Shen, S.C.; Chen, W.Y.; Aljuffali, I.A.; Suen, S.Y.; Fang, J.Y. Noninvasive delivery of siRNA and plasmid DNA into skin by fractional ablation: Erbium:YAG laser versus CO2 laser. Eur. J. Pharm. Biopharm., 2014, 86, 315-323.
[115]
Mitragotri, S. Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov., 2006, 5, 543-548.
[116]
Stachowiak, J.C.; Li, T.H.; Arora, A.; Mitragotri, S.; Fletcher, D.A. Dynamic control of needle-free jet injection. J. Control. Release, 2009, 135, 104-112.
[117]
Park, M.A.; Jang, H.J.; Sirotkin, F.V.; Yoh, J.J. Er:YAG laser pulse for small-dose splashback-free microjet transdermal drug delivery. Optics. Letts., 2012, 37, 3894-3896.
[118]
Jang, H.J.; Yu, H.; Lee, S.; Hur, E.; Kim, Y.; Lee, S.H.; Kang, N.; Yoh, J.J. Towards clinical use of a laser-induced microjet system aimed at reliable and safe drug delivery. J. Biomed. Optics., 2014, 19, 058001.
[119]
Jang, H.J.; Hur, E.; Kim, Y.; Lee, S.H.; Kang, N.G.; Yoh, J.J. Laser-induced microjet injection into preablated skin for more effective transdermal drug delivery. J. Biomed. Optics., 2014, 19, 118002.
[120]
Jang, H.J.; Yeo, S.; Yoh, J.J. Skin pre-ablation and laser assisted microjet injection for deep tissue penetration. Lasers Surg. Med., 2017, 49, 387-394.
[121]
Zilony, N.; Tzur-Balter, A.; Segal, E.; Shefi, O. Bombarding cancer: Biolistic delivery of therapeutics using porous Si carriers. Sci. Rep., 2013, 3, 2499.
[122]
Bergmann-Leitner, E.S.; Leitner, W.W. Improving DNA vaccines against malaria: Could immunization by gene gun be the answer? Therap. Deliv., 2013, 4, 767-770.
[123]
Wang, S.; Zhang, C.; Zhang, L.; Li, J.; Huang, Z.; Lu, S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine, 2008, 26, 2100-2110.
[124]
Bragstad, K.; Martel, C.J.; Thomsen, J.S.; Jensen, K.L.; Nielsen, L.P.; Aasted, B.; Fomsgaard, A. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades. Influenza Other Respir. Viruses, 2011, 5, 13-23.
[125]
Liu, Y.; Kendall, M.A. Optimization of a jet-propelled particle injection system for the uniform transdermal delivery of drug/vaccine. Biotechnol. Bioeng., 2007, 97, 1300-1308.
[126]
Quinn, H.L.; Kearney, M.C.; Courtenay, A.J.; McCrudden, M.T.; Donnelly, R.F. The role of microneedles for drug and vaccine delivery. Exp Opin. Drug Deliv., 2014, 11, 1769-1780.
[127]
Kim, Y.C.; Park, J.H.; Prausnitz, M.R. Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev., 2012, 64, 1547-1568.
[128]
Gill, H.S.; Denson, D.D.; Burris, B.A.; Prausnitz, M.R. Effect of microneedle design on pain in human volunteers. Clin. J. Pain, 2008, 24, 585-594.
[129]
Indermun, S.; Luttge, R.; Choonara, Y.E.; Kumar, P.; du Toit, L.C.; Modi, G.; Pillay, V. Current advances in the fabrication of microneedles for transdermal delivery. J. Control. Release, 2014, 185, 130-138.
[130]
Gupta, J.; Gill, H.S.; Andrews, S.N.; Prausnitz, M.R. Kinetics of skin resealing after insertion of microneedles in human subjects. J. Control. Release, 2011, 154, 148-155.
[131]
Gill, H.S.; Prausnitz, M.R. Coated microneedles for transdermal delivery. J. Control. Release, 2007, 117, 227-237.
[132]
Choi, H.J.; Yoo, D.G.; Bondy, B.J.; Quan, F.S.; Compans, R.W.; Kang, S.M.; Prausnitz, M.R. Stability of influenza vaccine coated onto microneedles. Biomaterials, 2012, 33, 3756-3769.
[133]
Vrdoljak, A.; McGrath, M.G.; Carey, J.B.; Draper, S.J.; Hill, A.V.; O’Mahony, C.; Crean, A.M.; Moore, A.C. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J. Control. Release, 2012, 159, 34-42.
[134]
Zhu, Q.; Zarnitsyn, V.G.; Ye, L.; Wen, Z.; Gao, Y.; Pan, L.; Skountzou, I.; Gill, H.S.; Prausnitz, M.R.; Yang, C.; Compans, R.W. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. USA, 2009, 106, 7968-7973.
[135]
Du, G.; Woythe, L.; van der Maaden, K.; Leone, M.; Romeijn, S.; Kros, A.; Kersten, G.; Jiskoot, W.; Bouwstra, J.A. Coated and hollow microneedle-mediated intradermal immunization in mice with diphtheria toxoid loaded mesoporous silica nanoparticles. Pharm. Res., 2018, 35, 189.
[137]
Dangol, M.; Kim, S.; Li, C.G.; Fakhraei Lahiji, S.; Jang, M.; Ma, Y.; Huh, I.; Jung, H. Anti-obesity effect of a novel caffeine-loaded dissolving microneedle patch in high-fat diet-induced obese C57BL/6J mice. J. Control. Release, 2017, 265, 41-47.
[138]
Zhao, X.; Li, X.; Zhang, P.; Du, J.; Wang, Y. Tip-loaded fast-dissolving microneedle patches for photodynamic therapy of subcutaneous tumor. J. Control. Release, 2018, 286, 201-209.
[139]
Lee, I.C.; Lin, W.M.; Shu, J.C.; Tsai, S.W.; Chen, C.H.; Tsai, M.T. Formulation of two-layer dissolving polymeric microneedle patches for insulin transdermal delivery in diabetic mice. J. Biomed. Mater. Res. Part A, 2017, 105, 84-93.
[140]
Chen, X.; Wang, L.; Yu, H.; Li, C.; Feng, J.; Haq, F.; Khan, A.; Khan, R.U. Preparation, properties and challenges of the microneedles-based insulin delivery system. J. Control. Release, 2018, 288, 173-188.
[141]
Zhu, W.; Pewin, W.; Wang, C.; Luo, Y.; Gonzalez, G.X.; Mohan, T.; Prausnitz, M.R.; Wang, B.Z. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines. J. Control. Release, 2017, 261, 1-9.
[142]
Rodgers, A.M.; Courtenay, A.J.; Donnelly, R.F. Dissolving microneedles for intradermal vaccination: Manufacture, formulation, and stakeholder considerations. Exp Opin. Drug Deliv., 2018, 15, 1039-1043.
[143]
Leone, M.; Priester, M.I.; Romeijn, S.; Nejadnik, M.R.; Monkare, J.; O’Mahony, C.; Jiskoot, W.; Kersten, G.; Bouwstra, J.A. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment. Eur. J. Pharm. Biopharm., 2019, 134, 49-59.
[144]
Jin, Q.; Chen, H.J.; Li, X.; Huang, X.; Wu, Q.; He, G.; Hang, T.; Yang, C.; Jiang, Z.; Li, E.; Zhang, A.; Lin, Z.; Liu, F.; Xie, X. Reduced graphene oxide nanohybrid-assembled microneedles as mini-invasive electrodes for real-time transdermal biosensing. Small, 2019, e1804298.
[145]
Martanto, W.; Moore, J.S.; Kashlan, O.; Kamath, R.; Wang, P.M.; O’Neal, J.M.; Prausnitz, M.R. Microinfusion using hollow microneedles. Pharm. Res., 2006, 23, 104-113.
[146]
Donnelly, R.F.; Mooney, K.; McCrudden, M.T.; Vicente-Perez, E.M.; Belaid, L.; Gonzalez-Vazquez, P.; McElnay, J.C.; Woolfson, A.D. Hydrogel-forming microneedles increase in volume during swelling in skin, but skin barrier function recovery is unaffected. J. Pharm. Sci., 2014, 103, 1478-1486.
[147]
Donnelly, R.F.; McCrudden, M.T.; Zaid Alkilani, A.; Larraneta, E.; McAlister, E.; Courtenay, A.J.; Kearney, M.C.; Singh, T.R.; McCarthy, H.O.; Kett, V.L.; Caffarel-Salvador, E.; Al-Zahrani, S.; Woolfson, A.D. Hydrogel-forming microneedles prepared from “super swelling” polymers combined with lyophilised wafers for transdermal drug delivery. PloS One, 2014, 9, e111547.
[148]
Seong, K.Y.; Seo, M.S.; Hwang, D.Y.; O’Cearbhaill, E.D.; Sreenan, S.; Karp, J.M.; Yang, S.Y. A self-adherent, bullet-shaped microneedle patch for controlled transdermal delivery of insulin. J. Control. Release: Off. J. Control. Release, 2017, 265, 48-56.
[149]
Donnelly, R.F.; Mooney, K.; Caffarel-Salvador, E.; Torrisi, B.M.; Eltayib, E.; McElnay, J.C. Microneedle-mediated minimally invasive patient monitoring. Ther. Drug Monit., 2014, 36, 10-17.
[151]
Prausnitz, M.R. Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. Annu. Rev. Chem. Biomol. Eng., 2017, 8, 177-200.
[152]
Ye, Y.; Yu, J.; Wen, D.; Kahkoska, A.R.; Gu, Z. Polymeric microneedles for transdermal protein delivery. Adv. Drug Deliv. Rev., 2018, 127, 106-118.
[153]
Nguyen, T.T.; Park, J.H. Human studies with microneedles for evaluation of their efficacy and safety. Exp Opin. Drug Deliv., 2018, 15, 235-245.
[154]
Arya, J.; Henry, S.; Kalluri, H.; McAllister, D.V.; Pewin, W.P.; Prausnitz, M.R. Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects. Biomaterials, 2017, 128, 1-7.
[155]
Donnelly, R.F.; Moffatt, K.; Alkilani, A.Z.; Vicente-Perez, E.M.; Barry, J.; McCrudden, M.T.; Woolfson, A.D. Hydrogel-forming microneedle arrays can be effectively inserted in skin by self-application: A pilot study centred on pharmacist intervention and a patient information leaflet. Pharm. Res., 2014, 31, 1989-1999.
[156]
Moffatt, K.; Wang, Y.; Raj Singh, T.R.; Donnelly, R.F. Microneedles for enhanced transdermal and intraocular drug delivery. Curr. Opin. Pharmacol., 2017, 36, 14-21.
[157]
Jin, X.; Zhu, D.D.; Chen, B.Z.; Ashfaq, M.; Guo, X.D. Insulin delivery systems combined with microneedle technology. Adv. Drug Deliv. Rev., 2018, 127, 119-137.
[158]
Raphael, A.P.; Primiero, C.A.; Ansaldo, A.B.; Keates, H.L.; Soyer, H.P.; Prow, T.W. Elongate microparticles for enhanced drug delivery to ex vivo and in vivo pig skin. J. Control. Release, 2013, 172, 96-104.
[159]
Raphael, A.P.; Primiero, C.A.; Lin, L.L.; Smith, R.F.; Dyer, P.; Soyer, H.P.; Prow, T.W. High aspect ratio elongated microparticles for enhanced topical drug delivery in human volunteers. Adv. Healthc. Mater., 2014, 3, 860-866.
[160]
Yamada, M.; Tayeb, H.; Wang, H.; Dang, N.; Mohammed, Y.H.; Osseiran, S.; Belt, P.J.; Roberts, M.S.; Evans, C.L.; Sainsbury, F.; Prow, T.W. Using elongated microparticles to enhance tailorable nanoemulsion delivery in excised human skin and volunteers. J. Control. Release, 2018, 288, 264-276.
[161]
Prow, T.W.; Mohammed, Y.H.; Ansaldo, A.B.; Benson, H.A.E. Topical microneedle drug delivery enhanced with magnetophoresis, in: Chilcott, R.P.; Brain, K.R. (Eds.)Advances in Dermatological Sciences; RSC Publishing, 2013, pp. 169-177.
[162]
Donnelly, R.F.; Garland, M.J.; Alkilani, A.Z. Microneedle-iontophoresis combinations for enhanced transdermal drug delivery. Methods Mol. Biol., 2014, 1141, 121-132.
[163]
Dragicevic, N.; Maibach, H. Combined use of nanocarriers and physical methods for percutaneous penetration enhancement. Adv. Drug Deliv. Rev., 2018, 127, 58-84.
[164]
Hickling, J.K.; Jones, K.R.; Friede, M.; Zehrung, D.; Chen, D.; Kristensen, D. Intradermal delivery of vaccines: Potential benefits and current challenges. Bull. World Health Organ., 2011, 89, 221-226.
[165]
Kupper, T.S.; Fuhlbrigge, R.C. Immune surveillance in the skin: Mechanisms and clinical consequences. Nat. Rev. Immunol., 2004, 4, 211-222.
[166]
Levin, C.; Perrin, H.; Combadiere, B. Tailored immunity by skin antigen-presenting cells. Hum. Vaccin. Immunother., 2015, 11, 27-36.
[167]
McNeilly, C.L.; Crichton, M.L.; Primiero, C.A.; Frazer, I.H.; Roberts, M.S.; Kendall, M.A. Microprojection arrays to immunise at mucosal surfaces. J. Control. Release, 2014, 196, 252-260.
[168]
Rouphael, N.G.; Paine, M.; Mosley, R.; Henry, S.; McAllister, D.V.; Kalluri, H.; Pewin, W.; Frew, P.M.; Yu, T.; Thornburg, N.J.; Kabbani, S.; Lai, L.; Vassilieva, E.V.; Skountzou, I.; Compans, R.W.; Mulligan, M.J.; Prausnitz, M.R. Group, T.-M.S. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): A randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet, 2017, 390, 649-658.
[169]
McAllister, L.; Anderson, J.; Werth, K.; Cho, I.; Copeland, K.; Le Cam Bouveret, N.; Plant, D.; Mendelman, P.M.; Cobb, D.K. Needle-free jet injection for administration of influenza vaccine: A randomised non-inferiority trial. Lancet, 2014, 384, 674-681.
[171]
Yousafzai, M.T.; Saleem, A.F.; Mach, O.; Baig, A.; Sutter, R.W.; Zaidi, A.K.M. Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan. Heliyon, 2017, 3, e00395.
[172]
Kim, Y.C.; Song, J.M.; Lipatov, A.S.; Choi, S.O.; Lee, J.W.; Donis, R.O.; Compans, R.W.; Kang, S.M.; Prausnitz, M.R. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur. J. Pharm. Biopharm., 2012, 81, 239-247.
[173]
Vassilieva, E.V.; Kalluri, H.; McAllister, D.; Taherbhai, M.T.; Esser, E.S.; Pewin, W.P.; Pulit-Penaloza, J.A.; Prausnitz, M.R.; Compans, R.W.; Skountzou, I. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv. Trans. Res., 2015, 5, 360-371.
[174]
Wei, J.C.J.; Haridass, I.N.; Crichton, M.L.; Mohammed, Y.H.; Meliga, S.C.; Sanchez, W.Y.; Grice, J.E.; Benson, H.A.E.; Roberts, M.S.; Kendall, M.A.F. Space- and time-resolved investigation on diffusion kinetics of human skin following macromolecule delivery by microneedle arrays. Sci. Rep., 2018, 8, 17759.
[175]
Fernando, G.J.; Chen, X.; Primiero, C.A.; Yukiko, S.R.; Fairmaid, E.J.; Corbett, H.J.; Frazer, I.H.; Brown, L.E.; Kendall, M.A. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J. Control. Release, 2012, 159, 215-221.
[176]
Fernando, G.J.; Zhang, J.; Ng, H.I.; Haigh, O.L.; Yukiko, S.R.; Kendall, M.A. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses. J. Control. Release, 2016, 237, 35-41.
[177]
Chen, X.; Kask, A.S.; Crichton, M.L.; McNeilly, C.; Yukiko, S.; Dong, L.; Marshak, J.O.; Jarrahian, C.; Fernando, G.J.; Chen, D.; Koelle, D.M.; Kendall, M.A. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J. Control. Release, 2010, 148, 327-333.
[178]
Corbett, H.J.; Fernando, G.J.; Chen, X.; Frazer, I.H.; Kendall, M.A. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PloS One, 2010, 5, e13460.
[179]
Muller, D.A.; Fernando, G.J.P.; Owens, N.S.; Agyei-Yeboah, C.; Wei, J.C.J.; Depelsenaire, A.C.I.; Forster, A.; Fahey, P.; Weldon, W.C.; Oberste, M.S.; Young, P.R.; Kendall, M.A.F. High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. Sci. Rep., 2017, 7, 12644.
[180]
Muller, D.A.; Pearson, F.E.; Fernando, G.J.; Agyei-Yeboah, C.; Owens, N.S.; Corrie, S.R.; Crichton, M.L.; Wei, J.C.; Weldon, W.C.; Oberste, M.S.; Young, P.R.; Kendall, M.A. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci. Rep., 2016, 6, 22094.
[181]
Baleeiro, R.B.; Wiesmuller, K.H.; Reiter, Y.; Baude, B.; Dahne, L.; Patzelt, A.; Lademann, J.; Barbuto, J.A.; Walden, P. Topical vaccination with functionalized particles targeting dendritic cells. J. Invest. Dermatol., 2013, 133, 1933-1941.
[182]
Gilliam, A.C.; Kremer, I.B.; Yoshida, Y.; Stevens, S.R.; Tootell, E.; Teunissen, M.B.; Hammerberg, C.; Cooper, K.D. The human hair follicle: A reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J. Invest. Dermatol., 1998, 110, 422-427.
[183]
Yu, J.; Zhang, Y.; Ye, Y.; DiSanto, R.; Sun, W.; Ranson, D.; Ligler, F.S.; Buse, J.B.; Gu, Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc. Natl. Acad. Sci. USA, 2015, 112, 8260-8265.
[184]
Lee, H.; Song, C.; Hong, Y.S.; Kim, M.S.; Cho, H.R.; Kang, T.; Shin, K.; Choi, S.H.; Hyeon, T.; Kim, D.H. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. Sci. Adv., 2017, 3, e1601314.
[185]
Lee, H.; Choi, T.K.; Lee, Y.B.; Cho, H.R.; Ghaffari, R.; Wang, L.; Choi, H.J.; Chung, T.D.; Lu, N.; Hyeon, T.; Choi, S.H.; Kim, D.H. A graphene-based electrochemical device with thermoresponsive microneedles for diabetes monitoring and therapy. Nat. Nanotechnol., 2016, 11, 566-572.
[186]
Son, D.; Lee, J.; Qiao, S.; Ghaffari, R.; Kim, J.; Lee, J.E.; Song, C.; Kim, S.J.; Lee, D.J.; Jun, S.W.; Yang, S.; Park, M.; Shin, J.; Do, K.; Lee, M.; Kang, K.; Hwang, C.S.; Lu, N.; Hyeon, T.; Kim, D.H. Multifunctional wearable devices for diagnosis and therapy of movement disorders. Nat. Nanotechnol., 2014, 9, 397-404.
